(Q47920560)

English

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

scientific article published on 12 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Kazuya Tanimura

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

K Haratani

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

H Hayashi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

T Tanaka

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

H Kaneda

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Y Togashi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

K Sakai

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

K Hayashi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

S Tomida

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Y Chiba

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

K Yonesaka

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Y Nonagase

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

T Takahama

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

J Tanizaki

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

K Tanaka

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

T Yoshida

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

M Takeda

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

H Yoshioka

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

T Ishida

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

T Mitsudomi

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

K Nishio

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

K Nakagawa

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

1 July 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1532-1539

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX183

21 January 2018

Identifiers

10.1093/ANNONC/MDX183

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28407039%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47920560&oldid=1288286549"